Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01023880 · ClinicalTrials.gov registry record · Phase 1
Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy
A Phase 1 study, sponsored by Cephalon.
- Terminated
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT01023880 is a Phase 1 study that was terminated before completion, run by Cephalon. The registered enrollment target is 62 participants.
The verdict
NCT01023880, a Phase 1 study, was terminated before completion, sponsored by Cephalon.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
The primary objective for part 1 of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in patients with relapsed and refractory multiple myeloma. The primary objective for part 2 is to evaluate the antitumor activity of CEP-18770 in patients treated at the MTD.
Interventions
- DRUG CEP-18770
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01023880
The ClinicalTrials.gov registry entry for NCT01023880 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CEP-18770 is the first listed.
NCT01023880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01023880 about?
NCT01023880 is a clinical study titled "Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy". The primary objective for part 1 of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in patients with relapsed and refractory multiple myeloma. The primary objective for part 2 is to evaluate the antitumor activity of CEP-18770 in patients treated at the MTD.
What is the current status of trial NCT01023880?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2010-01. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01023880?
The interventions under investigation include: CEP-18770 (DRUG).
Who is sponsoring clinical trial NCT01023880?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.